PDF(Pubmed)
Abstract：
UNASSIGNED: A nationwide cross-sectional epidemiological survey was conducted to capture the true extent of coronavirus disease 2019 (COVID-19) exposure in Senegal.
UNASSIGNED: Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wave of COVID-19 transmission. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were screened using three distinct ELISA assays. Adjusted prevalence rates for the survey design were calculated for each test separately, and thereafter combined. Crude and adjusted prevalence rates based on test performance were estimated to assess the seroprevalence. As some samples were collected in high malaria endemic areas, the relationship between SARS-CoV-2 seroreactivity and antimalarial humoral immunity was also investigated.
UNASSIGNED: Of the 1463 participants included in this study, 58.8% were female and 41.2% were male; their mean age was 29.2 years (range 0.20-84.8.0 years). The national seroprevalence was estimated at 28.4% (95% confidence interval 26.1-30.8%). There was substantial regional variability. All age groups were impacted, and the prevalence of SARS-CoV-2 was comparable in the symptomatic and asymptomatic groups. An estimated 4 744 392 (95% confidence interval 4 360 164-5 145 327) were potentially infected with SARS-CoV-2 in Senegal, while 16 089 COVID-19 RT-PCR laboratory-confirmed cases were reported by the national surveillance. No correlation was found between SARS-CoV-2 and Plasmodium seroreactivity.
UNASSIGNED: These results provide a better estimate of SARS-CoV-2 dissemination in the Senegalese population. Preventive and control measures need to be reinforced in the country and especially in the south border regions.
UNASSIGNED: Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wave of COVID-19 transmission. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were screened using three distinct ELISA assays. Adjusted prevalence rates for the survey design were calculated for each test separately, and thereafter combined. Crude and adjusted prevalence rates based on test performance were estimated to assess the seroprevalence. As some samples were collected in high malaria endemic areas, the relationship between SARS-CoV-2 seroreactivity and antimalarial humoral immunity was also investigated.
UNASSIGNED: Of the 1463 participants included in this study, 58.8% were female and 41.2% were male; their mean age was 29.2 years (range 0.20-84.8.0 years). The national seroprevalence was estimated at 28.4% (95% confidence interval 26.1-30.8%). There was substantial regional variability. All age groups were impacted, and the prevalence of SARS-CoV-2 was comparable in the symptomatic and asymptomatic groups. An estimated 4 744 392 (95% confidence interval 4 360 164-5 145 327) were potentially infected with SARS-CoV-2 in Senegal, while 16 089 COVID-19 RT-PCR laboratory-confirmed cases were reported by the national surveillance. No correlation was found between SARS-CoV-2 and Plasmodium seroreactivity.
UNASSIGNED: These results provide a better estimate of SARS-CoV-2 dissemination in the Senegalese population. Preventive and control measures need to be reinforced in the country and especially in the south border regions.
摘要：
■进行了一项全国性的横断面流行病学调查，以了解塞内加尔2019年冠状病毒病（COVID-19）暴露的真实程度。
■在2020年10月至11月，即第一波COVID-19传播结束时，对家庭进行了多阶段随机整群抽样。使用三种不同的ELISA测定法筛选抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体。分别计算每个测试的调查设计的调整后患病率，此后合并。估计了基于测试表现的粗略和调整后的患病率，以评估血清阳性率。由于一些样本是在疟疾高流行地区收集的，还研究了SARS-CoV-2血清反应性与抗疟疾体液免疫之间的关系。
■在本研究的1463名参与者中，58.8％为女性，41.2％为男性；他们的平均年龄为29.2岁（范围为0.20-84.8.0岁）。全国血清阳性率估计为28.4%（95%置信区间26.1-30.8%）。区域差异很大。所有年龄组都受到影响，SARS-CoV-2的患病率在有症状和无症状组中相当。估计有4744392（95％置信区间4360164-5145327）在塞内加尔可能感染了SARS-CoV-2，国家监测报告了16089例COVID-19RT-PCR实验室确诊病例。SARS-CoV-2与疟原虫血清反应性之间未发现相关性。
■这些结果为SARS-CoV-2在塞内加尔人群中的传播提供了更好的估计。该国，特别是南部边境地区，需要加强预防和控制措施。
■在2020年10月至11月，即第一波COVID-19传播结束时，对家庭进行了多阶段随机整群抽样。使用三种不同的ELISA测定法筛选抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体。分别计算每个测试的调查设计的调整后患病率，此后合并。估计了基于测试表现的粗略和调整后的患病率，以评估血清阳性率。由于一些样本是在疟疾高流行地区收集的，还研究了SARS-CoV-2血清反应性与抗疟疾体液免疫之间的关系。
■在本研究的1463名参与者中，58.8％为女性，41.2％为男性；他们的平均年龄为29.2岁（范围为0.20-84.8.0岁）。全国血清阳性率估计为28.4%（95%置信区间26.1-30.8%）。区域差异很大。所有年龄组都受到影响，SARS-CoV-2的患病率在有症状和无症状组中相当。估计有4744392（95％置信区间4360164-5145327）在塞内加尔可能感染了SARS-CoV-2，国家监测报告了16089例COVID-19RT-PCR实验室确诊病例。SARS-CoV-2与疟原虫血清反应性之间未发现相关性。
■这些结果为SARS-CoV-2在塞内加尔人群中的传播提供了更好的估计。该国，特别是南部边境地区，需要加强预防和控制措施。
